膵臓がん治療薬の世界市場レポート 2025年

膵臓がん治療薬の市場規模は、今後数年間で安定した成長が見込まれます。2029年にはCAGR3.8％で47億6,000万米ドルに成長します。予測期間の成長は、がん罹患率の増加、ヘルスケア支出の増加、政府支援の増加に起因しています。予測期間における主な動向としては、膵臓がん治療のための新薬開発への注力、新規ナノメディシン治療への注力、投資拡大への注力、戦略的提携への注力、製品イノベーションへの注力などが挙げられます。

膵臓がん治療薬市場の予想成長は、膵臓がんの有病率の増加によってもたらされます。膵臓がん患者数の増加は医薬品需要を押し上げ、結果として市場成長を促進すると予想されます。がん患者の急増は、人口の高齢化や肥満に対処する人の増加といった要因に起因するところが大きいです。例えば、米国がん協会は、2023年に約64,050人（男性33,130人、女性30,920人）が膵臓がんの診断を受け、約50,550人（男性26,620人、女性23,930人）が膵臓がんで死亡すると推定しています。

膵臓がん研究を目的とした政府の取り組みや資金援助が、今後数年間の膵臓がん治療薬市場の成長を大きく促進すると予想されます。これらのイニシアチブは、公衆衛生を強化し、患者の転帰を改善するプロジェクトに焦点を当てた事業体に財政的支援を提供します。例えば、2024年6月、米国の政府機関である国立衛生研究所（National Institutes of Health）は、膵臓がん調査への資金増額を報告し、2021年の推定2億1,810万米ドルから2022年には2億2,680万米ドルに増加しました。この資金援助の増加は、膵臓がん患者のQOLと生存率を向上させるという政府のコミットメントを強調するものであり、それによって市場開拓における薬剤開発と治療選択肢の進歩が促進されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界膵臓がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の膵臓がん治療薬市場：成長率分析
• 世界の膵臓がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の膵臓がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界膵臓がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の膵臓がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 膵臓神経内分泌がん治療薬
• 膵外分泌がん治療薬
• 世界の膵臓がん治療薬市場薬剤の組み合わせによる、実績と予測, 2019-2024, 2024-2029F, 2034F
• シングル
• ダブル
• トリプレット
• 四つ子
• 世界の膵臓がん治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他のエンドユーザー
• 世界の膵臓がん治療薬市場膵臓神経内分泌がん治療薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ソマトスタチン類似体
• 標的治療薬
• 化学療法剤
• 世界の膵臓がん治療薬市場膵外分泌がん治療薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法剤
• 標的治療薬
• 免疫療法薬

第7章 地域別・国別分析

• 世界の膵臓がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の膵臓がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 膵臓がん治療薬市場：競合情勢
• 膵臓がん治療薬市場：企業プロファイル
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbvie Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries
• Amgen Incorporation
• Eli Lilly And Company
• Beigene
• Chi-Med
• Cstone Pharmaceuticals
• Voxtur Bio Ltd
• Shantu Pharma
• Krushi Mitra
• Kremedine Health Private Limited
• Arlak Biotech
• Healthkind Labs Pvt. Ltd
• Swisschem Healthcare Pvt Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 膵臓がん治療薬市場2029：新たな機会を提供する国
• 膵臓がん治療薬市場2029：新たな機会を提供するセグメント
• 膵臓がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Pancreatic cancer drugs refer to medications designed for treating pancreatic cancer, a condition resulting from uncontrolled cell growth in the pancreas. This abnormal growth disrupts the pancreas' production of digestive juices and hormones responsible for regulating blood sugar levels. Tissue lumps, known as tumors, develop due to this excessive cell growth, impeding the normal functioning of the pancreas.

Pancreatic cancer drugs can be categorized into two main types endocrine pancreatic cancer and exocrine pancreatic cancer. Exocrine pancreatic cells generate enzymes released into the small intestine to aid in the digestion of food as it traverses the digestive tract. The diverse range of drugs for pancreatic cancer treatment includes Afinitor, erlotinib, hydrochloride everolimus, 5-FU (fluorouracil), gemcitabine, and Abraxane. These drugs find application in various healthcare settings, including hospitals, clinics, and others.

The pancreatic cancer drugs market research report is one of a series of new reports from The Business Research Company that provides pancreatic cancer drugs market statistics, including pancreatic cancer drugs industry global market size, regional shares, competitors with a pancreatic cancer drugs market share, detailed pancreatic cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer drugs industry. This pancreatic cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic cancer drugs market size has grown steadily in recent years. It will grow from $3.96 billion in 2024 to $4.1 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to strong economic growth in emerging markets, an increasing aging population and an increasing prevalence of pancreatic cancer.

The pancreatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $4.76 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to an increase in cancer incidence rates, a rise in healthcare expenditure and increasing government support. Major trends in the forecast period include focus on developing new drugs to treat pancreatic cancer, focus on novel nanomedicine treatment, focus on increasing investments, focus on strategic collaborations and focus on product innovations.

The anticipated growth of the pancreatic cancer drugs market is driven by the increasing prevalence of pancreatic cancer. The elevated number of pancreatic cancer cases is expected to boost the demand for drugs, consequently fueling market growth. The surge in cancer instances is largely attributed to factors such as an aging population and a growing number of people dealing with obesity. For example, the American Cancer Society estimates that in 2023, approximately 64,050 individuals (33,130 men and 30,920 women) will receive a pancreatic cancer diagnosis, and about 50,550 people (26,620 men and 23,930 women) will succumb to pancreatic cancer.

Government initiatives and funding aimed at pancreatic cancer research are expected to significantly drive the growth of the pancreatic cancer drugs market in the coming years. These initiatives provide financial support to entities focused on projects that enhance public health and improve patient outcomes. For example, in June 2024, the National Institutes of Health, a US-based government agency, reported an increase in funding for pancreatic cancer research, rising from an estimated $218.1 million in 2021 to $226.8 million in 2022. This boost in financial support underscores the government's commitment to improving the quality of life and survival rates for patients affected by pancreatic cancer, thereby fostering advancements in drug development and treatment options within the market.

An ongoing trend in the pancreatic cancer drugs market is the preference for combination therapy over monotherapy. Recognizing the potential to enhance drug efficacy and improve the survival rates of patients with pancreatic cancer, major players in the market are increasingly exploring the combination of two or more drugs. Companies such as Rafael Pharmaceuticals have initiated pivotal Phase 3 trials, such as AVENGER 500, combining CPI-613 (delimitate) with Modified FOLFIRINOX as a first-line treatment for patients with Metastatic Pancreatic Cancer. Apexigen, Inc., a clinical-stage biopharmaceutical company, is also investing in combination therapy, presenting new clinical data on APX005M for patients with metastatic pancreatic cancer.

To gain a competitive edge, major companies in the pancreatic cancer drugs market are investing in local drug delivery systems. This approach involves administering drugs directly to the site of action, enhancing efficacy while minimizing side effects. For instance, OncoLize, a Netherlands-based company, raised a US$ 1.7 million seed investment round in April 2023 to extend their preclinical success with a local drug delivery system for treating pancreatic and lung cancer. This innovative product utilizes unique liquid formulations to deliver a variety of anti-cancer drugs more effectively, both traditional chemotherapy drugs and modern immuno-drugs.

In October 2022, Pfizer Inc., a prominent US-based pharmaceutical company, acquired Biohaven Pharmaceuticals for an undisclosed amount. This strategic acquisition is part of Pfizer's efforts to enhance its portfolio with innovative migraine treatments, particularly focusing on CGRP receptor antagonists such as NURTEC ODT and zavegepant. With an aim to tap into the substantial revenue potential in the migraine market-projected to exceed $6 billion-this move aligns with Pfizer's broader strategy to expand its internal medicine pipeline through 2030 and beyond. Biohaven Pharmaceuticals is known for its expertise in developing novel treatments, including antibody-drug conjugates for various conditions, which complements Pfizer's growth objectives in the pharmaceutical landscape.

Major companies operating in the pancreatic cancer drugs market include Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Novartis AG, Abbvie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries, Amgen Incorporation, Eli Lilly And Company, Beigene, Chi-Med, Cstone Pharmaceuticals, Voxtur Bio Ltd, Shantu Pharma, Krushi Mitra, Kremedine Health Private Limited, Arlak Biotech, Healthkind Labs Pvt. Ltd, Swisschem Healthcare Pvt Ltd, Apikos Pharma, GlaxoSmithKline Plc, Veropharm, Biocad, Celon Pharma, Celgene Corporation, Johnson & Johnson, Bayer AG, Tabuk Pharmaceuticals, Julphar Life Sciences, Eurolab, Sanofi, Aspen, Zahraa Oncology

North America was the largest region in the pancreatic cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the global pancreatic cancer drugs market share during the forecast period. The regions covered in the pancreatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pancreatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The pancreatic cancer drugs market consists of sales of Gemcitabine (Gemzar), 5-fluorouracil (5-FU), and Irinotecan (Camptosar). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Pancreatic Neuroendocrine Cancer Drugs, Pancreatic Exocrine Cancer Drugs
• 2) By Drug Combination: Single, Double, Triplet, Quadruplet
• 3) By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
• Subsegments:
• 1) By Pancreatic Neuroendocrine Cancer Drugs: Somatostatin Analogs; Targeted Therapy Drugs; Chemotherapy Agents
• 2) By Pancreatic Exocrine Cancer Drugs: Chemotherapy Agents; Targeted Therapy Drugs; Immunotherapy Drugs
• Companies Mentioned: Bristol-Myers Squibb Company; Pfizer Inc.; AstraZeneca PLC; F. Hoffmann-La Roche AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pancreatic Cancer Drugs Market Characteristics

3. Pancreatic Cancer Drugs Market Trends And Strategies

4. Pancreatic Cancer Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Pancreatic Cancer Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pancreatic Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pancreatic Cancer Drugs Market Growth Rate Analysis
• 5.4. Global Pancreatic Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pancreatic Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pancreatic Cancer Drugs Total Addressable Market (TAM)

6. Pancreatic Cancer Drugs Market Segmentation

• 6.1. Global Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pancreatic Neuroendocrine Cancer Drugs
• Pancreatic Exocrine Cancer Drugs
• 6.2. Global Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single
• Double
• Triplet
• Quadruplet
• 6.3. Global Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other End-Users
• 6.4. Global Pancreatic Cancer Drugs Market, Sub-Segmentation Of Pancreatic Neuroendocrine Cancer Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Somatostatin Analogs
• Targeted Therapy Drugs
• Chemotherapy Agents
• 6.5. Global Pancreatic Cancer Drugs Market, Sub-Segmentation Of Pancreatic Exocrine Cancer Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy Agents
• Targeted Therapy Drugs
• Immunotherapy Drugs

7. Pancreatic Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Pancreatic Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pancreatic Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pancreatic Cancer Drugs Market

• 8.1. Asia-Pacific Pancreatic Cancer Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pancreatic Cancer Drugs Market

• 9.1. China Pancreatic Cancer Drugs Market Overview
• 9.2. China Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pancreatic Cancer Drugs Market

• 10.1. India Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pancreatic Cancer Drugs Market

• 11.1. Japan Pancreatic Cancer Drugs Market Overview
• 11.2. Japan Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pancreatic Cancer Drugs Market

• 12.1. Australia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pancreatic Cancer Drugs Market

• 13.1. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pancreatic Cancer Drugs Market

• 14.1. South Korea Pancreatic Cancer Drugs Market Overview
• 14.2. South Korea Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pancreatic Cancer Drugs Market

• 15.1. Western Europe Pancreatic Cancer Drugs Market Overview
• 15.2. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pancreatic Cancer Drugs Market

• 16.1. UK Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pancreatic Cancer Drugs Market

• 17.1. Germany Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pancreatic Cancer Drugs Market

• 18.1. France Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pancreatic Cancer Drugs Market

• 19.1. Italy Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pancreatic Cancer Drugs Market

• 20.1. Spain Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pancreatic Cancer Drugs Market

• 21.1. Eastern Europe Pancreatic Cancer Drugs Market Overview
• 21.2. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pancreatic Cancer Drugs Market

• 22.1. Russia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pancreatic Cancer Drugs Market

• 23.1. North America Pancreatic Cancer Drugs Market Overview
• 23.2. North America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pancreatic Cancer Drugs Market

• 24.1. USA Pancreatic Cancer Drugs Market Overview
• 24.2. USA Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pancreatic Cancer Drugs Market

• 25.1. Canada Pancreatic Cancer Drugs Market Overview
• 25.2. Canada Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pancreatic Cancer Drugs Market

• 26.1. South America Pancreatic Cancer Drugs Market Overview
• 26.2. South America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pancreatic Cancer Drugs Market

• 27.1. Brazil Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pancreatic Cancer Drugs Market

• 28.1. Middle East Pancreatic Cancer Drugs Market Overview
• 28.2. Middle East Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pancreatic Cancer Drugs Market

• 29.1. Africa Pancreatic Cancer Drugs Market Overview
• 29.2. Africa Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pancreatic Cancer Drugs Market, Segmentation By Drug Combination, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pancreatic Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Pancreatic Cancer Drugs Market Competitive Landscape
• 30.2. Pancreatic Cancer Drugs Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Pancreatic Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Abbvie Inc.
• 31.2. Merck & Co., Inc.
• 31.3. Teva Pharmaceutical Industries
• 31.4. Amgen Incorporation
• 31.5. Eli Lilly And Company
• 31.6. Beigene
• 31.7. Chi-Med
• 31.8. Cstone Pharmaceuticals
• 31.9. Voxtur Bio Ltd
• 31.10. Shantu Pharma
• 31.11. Krushi Mitra
• 31.12. Kremedine Health Private Limited
• 31.13. Arlak Biotech
• 31.14. Healthkind Labs Pvt. Ltd
• 31.15. Swisschem Healthcare Pvt Ltd

32. Global Pancreatic Cancer Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pancreatic Cancer Drugs Market

34. Recent Developments In The Pancreatic Cancer Drugs Market

35. Pancreatic Cancer Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Pancreatic Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pancreatic Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pancreatic Cancer Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer